NCT03241446View on ClinicalTrials.gov

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2018

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Tilmanocept

Intravenously administered Technetium Tc 99m tilmanocept

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY

NCT03241446 - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA) | Biotech Hunter | Biotech Hunter